Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATOther Gross PP&E Adjustments
Ratios

KalVista Pharmaceuticals (KALV) Receivables Refunds (2017 - 2024)

KalVista Pharmaceuticals' Receivables Refunds history spans 8 years, with the latest figure at $11.4 million for Q4 2024.

  • For Q4 2024, Receivables Refunds changed N/A year-over-year to $11.4 million; the TTM value through Dec 2024 reached $11.4 million, changed N/A, while the annual FY2024 figure was $1.0 million, N/A changed from the prior year.
  • Receivables Refunds for Q4 2024 was $11.4 million at KalVista Pharmaceuticals, up from $965000.0 in the prior quarter.
  • Across five years, Receivables Refunds topped out at $16.5 million in Q2 2020 and bottomed at $954000.0 in Q4 2023.
  • The 4-year median for Receivables Refunds is $9.5 million (2021), against an average of $8.2 million.
  • The largest annual shift saw Receivables Refunds surged 65.03% in 2020 before it crashed 48.73% in 2021.
  • A 4-year view of Receivables Refunds shows it stood at $14.7 million in 2020, then plummeted by 48.32% to $7.6 million in 2021, then crashed by 87.43% to $954000.0 in 2023, then soared by 1096.75% to $11.4 million in 2024.
  • Per Business Quant, the three most recent readings for KALV's Receivables Refunds are $11.4 million (Q4 2024), $965000.0 (Q4 2024), and $1.0 million (Q2 2024).